10,901 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Eisler Capital UK Ltd.

Eisler Capital UK Ltd. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,901 shares of the medical device company’s stock, valued at approximately $1,353,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. DSM Capital Partners LLC acquired a new stake in DexCom during the fourth quarter worth about $28,000. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. grew its holdings in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the period. Smithfield Trust Co grew its holdings in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 165 shares during the period. Finally, Washington Trust Advisors Inc. grew its holdings in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 4,137 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $140.00, for a total value of $579,180.00. Following the completion of the sale, the executive vice president now owns 76,304 shares in the company, valued at approximately $10,682,560. The disclosure for this sale can be found here. Insiders have sold 187,293 shares of company stock worth $25,295,452 over the last quarter. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on DXCM shares. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a report on Sunday. Finally, UBS Group lifted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $140.94.

DexCom Trading Up 1.9 %

NASDAQ:DXCM traded up $2.25 on Wednesday, reaching $118.96. The company’s stock had a trading volume of 422,328 shares, compared to its average volume of 2,892,450. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm has a market cap of $47.31 billion, a price-to-earnings ratio of 76.17, a price-to-earnings-growth ratio of 2.82 and a beta of 1.22. The stock has a 50 day moving average price of $131.03 and a 200 day moving average price of $125.73.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. On average, equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.